ArticleBlood advances2019
Ponatinib treatment promotes arterial thrombosis and hyperactive platelets.
Abstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity.International journal of molecular sciences · 2026Article
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis.Blood vessels, thrombosis & hemostasis · 2026Article
- Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.Journal of thrombosis and thrombolysis · 2026Review
- Article
- KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3Molecular cancer · 2025Article
- Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis.Pharmaceutics · 2024Article
- Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024Article
- Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.PloS one · 2023Article
- Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data.Frontiers in cardiovascular medicine · 2022Review
- Article
- Cancer Therapy-Associated Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.International journal of molecular sciences · 2020Review
- SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.EBioMedicine · 2020Review
- Mechanisms, Clinical Phenotype and Potential Risk Prediction for Cardiovascular Toxicity Induced by Tyrosine Kinase Inhibitors In Chronic Myeloid Leukemia.Dose-response : a publication of International Hormesis SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Alona MerkulovaDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Steven C MitchellDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.ORCID 0000-0002-8347-3537
Evi X StavrouDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.ORCID 0000-0002-6075-7609
Gabriel L ForbesDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.
Alvin H SchmaierDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH.ORCID 0000-0002-3884-6234
Funding
Contact Pathway Activation on Vascular DevicesR01HL144113 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HINDS, MONICA T, MCCARTY, OWEN J · 2018 to 2025
$6.0MNovel approaches to improve prediction of cancer-associated thrombosisU01HL143402 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI KHORANA, ALOK A, MCCRAE, KEITH R. · 2018 to 2022
$4.7MREGULATION OF KININ DELIVERY ON HUVECR01HL052779 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHMAIER, ALVIN H · 1996 to 2013
$4.6MKruppel-Like Factor 2 Counters Vascular and Immunologic Dysfunction in Child Cerebral MalariaR01AI130131 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KAZURA, JAMES WALTER · 2017 to 2021
$3.0MMRP-14, CD36 and ThrombosisR01HL126645 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SIMON, DANIEL I · 2016 to 2019
$2.0MTargeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic WoundsR01HL137695 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI STAVROU, EVI X. · 2019 to 2023
$2.0MTyrosine Kinases and ThrombosisR01HL157405 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SCHMAIER, ALVIN H · 2022 to 2025
$1.9MPonatinib Induces Vascular Events in CML-Mechanisms and CorrectionR21CA223301 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI SCHMAIER, ALVIN H · 2019 to 2020
$397kTreatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in NeutrophilsI01BX003851 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI Evi X. Stavrou · 2020 to 2026
–NCI NIH HHS R21 CA223301NHLBI NIH HHS R01 HL052779NHLBI NIH HHS R01 HL126645NHLBI NIH HHS R01 HL137695NHLBI NIH HHS R01 HL144113NHLBI NIH HHS R01 HL157405NHLBI NIH HHS U01 HL143402NIAID NIH HHS R01 AI130131
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsArteriesBiomarkersBlood PlateletsDisease Models, AnimalDrug InteractionsImidazolesMicePioglitazoneProtein Kinase InhibitorsPyridazinesReactive Oxygen SpeciesThrombosisAntineoplastic AgentsBiomarkersImidazolesPioglitazoneponatinibProtein Kinase InhibitorsPyridazinesReactive Oxygen Species
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.